South Africa / Aspen Inks Deal to Manufacture J&J’s COVID-19 Vaccine
South African firm Aspen has inked a deal with Johnson & Johnson for the technical transfer and proposed…
Dr Reddy’s Laboratories South Africa
Last updated: 13.02.2014
Address: South Wing, The Place, 1 Sandton Drive, Sandton, 2196
P O Box 784746, Sandton City, Sandton, 2146 ,South Africa
Tel: (+27-11) 783 0104
Web: http://www.drreddys.com/southafrica/
Company description
Dr. Reddy’s – South Africa operation is a wholly-owned subsidiary and one of the leading generics players in the country. With a dedicated field force it focuses on key therapeutic areas like Central Nervous System (CNS) and Primary Care.
The business performance in South Africa has been phenomenal in the last few years. The overall revenue as per FY10 has been at $9.4 million enlisting a 56% growth.
Its advantageous position is ensured through the presence of key contributors in its business model. The Research & Development capability helps the company ensure enhanced FTL Opportunities through non-infringing pdts and supports differentiation with products and competitors. Alongside, the in-house API manufacturing capabilities assures cost competitiveness in both private and tender based markets. The company’s Formulation capabilities and strong business development team ensures high-quality in-house product pipeline, shapes licensing strategy to maximize market share and enrich the product basket. All the more its committed filed force has also been promising in recent years while reaching to all segments of the market.
In the South Africa Generic market Dr. Reddy’s is ranked 18th in terms of Value and 20th in terms of volume (Source: IMS-SA IGMS, MAT, Nov. 2010).
Products and services
Top-five products including Omez, Cifloc, Citraz, Amlate and DRL-Moxifloxacin contribute to over 50% of revenue.
Products cathegories:
Active Pharma Ingredients (API)
Custom Pharma Services (CPS)
Global Generics
New Chemical Entities (NCEs)
Differentiated Formulations
Biosimilars
Related
Opinion / Malaria Prevention Cannot be Allowed to Stall During the COVID-19 Pandemic
As COVID-19 threatens to derail more than a decade’s worth of hard-won gains in the fight against malaria, Dr…
COVID-19 / Cipla to Begin Manufacturing Remdesivir in South Africa
The South African affiliate of Indian pharma firm Cipla will begin manufacturing and distribution of remdesivir, a…
News Roundup / South Africa Pharma June 2020
Below is a roundup of latest news from South Africa’s life sciences and healthcare industries, including a…
Rare Diseases in South Africa: Bridging the Gap for Inclusive Healthcare
Kelly du Plessis is CEO & Founder of Rare Diseases South Africa, a registered NPO born out of necessity when…
Medical Device Segment braced for change in South Africa
Trailing behind South Africa’s pharmaceutical market in both value and growth, the nation’s medical device…
Tackling South Africa’s “Intimate Healthcare” Needs
The traditional model of healthcare has generally been limited to treatment in health facilities. But, when it…
South African Clinical Trials: Turning Diversity into Opportunity
Eclectic demographics, rapid patient recruitment, and a burgeoning population with a gradient of disease…
Showcasing South African innovation
While South Africa faces a distinct set of challenges in effectively managing its healthcare sector, the ecosystem…
Interview: Andre Buhrlen – Managing Director, Hersol Manufacturing…
Hersol prides itself on producing high-quality products and is today one of the leading Pharmaceutical Contract…
Interview: Albert Denoon – Owner, Baroque Medical, – Board Member,…
Albert Denoon (AB) and Jeff Hampton (JH) illustrate how the Crossroads and Campbell Institutes, two non-profit…
Interview: Charl De Klerk – General Manager, Bard South Africa
The general manager of Bard SA, Charl De Klerk, illustrates the company’s growth ambitions within South Africa…
